Thermo Fisher Scientific Inc (TMO) Holdings Lowered by Klingenstein Fields & Co. LLC

Klingenstein Fields & Co. LLC trimmed its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 11.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 147,015 shares of the medical research company’s stock after selling 18,228 shares during the quarter. Klingenstein Fields & Co. LLC’s holdings in Thermo Fisher Scientific were worth $27,815,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Rockland Trust Co. raised its holdings in shares of Thermo Fisher Scientific by 8.1% in the 3rd quarter. Rockland Trust Co. now owns 58,111 shares of the medical research company’s stock worth $10,995,000 after purchasing an additional 4,350 shares in the last quarter. Gabelli Funds LLC raised its holdings in shares of Thermo Fisher Scientific by 3.4% in the 3rd quarter. Gabelli Funds LLC now owns 150,500 shares of the medical research company’s stock worth $28,475,000 after purchasing an additional 5,000 shares in the last quarter. Gamco Investors INC. ET AL raised its holdings in shares of Thermo Fisher Scientific by 14.1% in the 3rd quarter. Gamco Investors INC. ET AL now owns 49,030 shares of the medical research company’s stock worth $9,276,000 after purchasing an additional 6,065 shares in the last quarter. Norris Perne & French LLP MI raised its holdings in shares of Thermo Fisher Scientific by 1.6% in the 3rd quarter. Norris Perne & French LLP MI now owns 53,297 shares of the medical research company’s stock worth $10,084,000 after purchasing an additional 841 shares in the last quarter. Finally, Veritas Asset Management LLP raised its holdings in shares of Thermo Fisher Scientific by 44.1% in the 3rd quarter. Veritas Asset Management LLP now owns 3,503,259 shares of the medical research company’s stock worth $662,817,000 after purchasing an additional 1,072,500 shares in the last quarter. Institutional investors own 85.32% of the company’s stock.

In related news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total transaction of $721,090.92. Following the transaction, the vice president now directly owns 19,751 shares in the company, valued at $3,657,490.18. The disclosure for this sale can be found here. Insiders have sold 56,280 shares of company stock worth $10,572,385 in the last 90 days. 0.49% of the stock is owned by company insiders.

TMO has been the topic of a number of research reports. Leerink Swann boosted their target price on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a report on Monday, October 9th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 target price on the stock in a report on Thursday, September 21st. Cowen Inc reiterated an “outperform” rating and issued a $220.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Deutsche Bank AG set a $226.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. Finally, BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $205.71.

Thermo Fisher Scientific Inc (NYSE:TMO) traded up $0.76 during mid-day trading on Monday, hitting $193.51. 374,400 shares of the stock were exchanged, compared to its average volume of 1,537,888. Thermo Fisher Scientific Inc has a twelve month low of $139.07 and a twelve month high of $201.20. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The firm has a market capitalization of $77,190.00, a price-to-earnings ratio of 21.26, a P/E/G ratio of 1.77 and a beta of 1.08.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same quarter in the previous year, the business earned $2.03 earnings per share. The firm’s revenue was up 13.9% compared to the same quarter last year. equities research analysts predict that Thermo Fisher Scientific Inc will post 9.36 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.

ILLEGAL ACTIVITY WARNING: “Thermo Fisher Scientific Inc (TMO) Holdings Lowered by Klingenstein Fields & Co. LLC” was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/27/thermo-fisher-scientific-inc-tmo-holdings-lowered-by-klingenstein-fields-co-llc.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply